论文部分内容阅读
目的观察布地奈德联合孟鲁司特钠治疗小儿支气管哮喘的临床疗效。方法选取东方市人民医院2013年11月—2015年12月收治的98例小儿支气管哮喘患儿,随机分为单一组与联合组,各49例。单一组应用布地奈德治疗,联合组应用布地奈德联合孟鲁司特钠治疗。观察两组患儿临床疗效、治疗前后肺功能指标〔用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、呼气峰值流速(PEF)及FEV1与FVC的比值(FEV1/FVC)〕及不良反应发生情况。结果联合组患儿总有效率高于单一组,差异有统计学意义(P<0.05)。治疗前,两组患儿肺功能指标比较,差异无统计学意义(P>0.05);治疗后,联合组患儿FEV1、FEV1/FVC、PEF、FVC高于单一组,差异有统计学意义(P<0.05)。两组患儿不良反应发生率比较,差异无统计学意义(P>0.05)。结论布地奈德与孟鲁司特钠联合治疗小儿支气管哮喘可显著提高其临床疗效,可有效改善肺功能指标,且未增加不良反应。
Objective To observe the clinical efficacy of budesonide combined with montelukast sodium in the treatment of pediatric bronchial asthma. METHODS: A total of 98 children with bronchial asthma admitted from November 2013 to December 2015 in Dongfang People’s Hospital were randomly divided into single group and combined group, with 49 cases in each group. Budesonide was given to a single group and to budesonide plus montelukast sodium in the combination group. The clinical curative effect, pulmonary function indexes (FVC, FEV1, PEF and FEV1 / FVC) before and after treatment were observed. And adverse reactions occurred. Results The total effective rate of children in combined group was higher than that of single group, the difference was statistically significant (P <0.05). Before treatment, there was no significant difference in pulmonary function indexes between the two groups (P> 0.05). After treatment, the FEV1, FEV1 / FVC, PEF and FVC in children in the combined group were higher than those in the single group P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion The combination of budesonide and montelukast sodium in children with bronchial asthma can significantly improve its clinical efficacy, can effectively improve the lung function, and did not increase the adverse reactions.